A new study shows that people Zepbound lost about 50% more weight than those using Wegovy. It was the first head-to-head ...

Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, ...

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

The head-to-head examination of these weight loss drugs provides doctors with 'robust' data on their effectiveness.

Key Takeaways Zepbound helped patients lose 50 pounds, compared to 33 pounds with WegovyThe study showed Zepbound users lost ...

Online weight-loss company Noom has begun offering smaller doses of compounded versions of Novo Nordisk's Wegovy as the U.S.

The obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk’s Wegovy in ...

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.

Eli Lilly & Co.’s obesity drug Zepbound helped people trim about two inches more off their waists than Novo Nordisk A/S’s Wegovy in the first head-to-head study of the rival medicines.

Zepbound Outperforms Wegovy in Head-to-Head Weight Loss Study MONDAY, May 12, 2025 (HealthDay News) — A new study has found that people taking Eli Lilly’s obesity drug Zepbound lost almost 50% ...

A new study has found that people taking Eli Lilly's obesity drug Zepbound lost almost 50% more weight than those using Novo Nordisk's Wegovy. The study, published in the New England Journal of ...